{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-24-000006","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.648074+00:00","generated_at":"2026-06-07T02:02:08.218148+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Exagen reports record AVISE CTD volume of ~137k units, reaffirms FY2023 guidance","bullets":["Record AVISE® CTD testing volume of approx. 137,000 units in FY2023.","Cash balance of $36.5M as of Dec 31, 2023; AR approx. $7M.","Reaffirms FY2023 revenue guidance of at least $50M, non-GAAP adjusted EBITDA of approx. -$20M.","Management points to streamlined operations and revamped expense structure toward profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-24-000006","json":"https://secwatch.observer/filing/0001274737-24-000006.json","markdown":"https://secwatch.observer/filing/0001274737-24-000006.md","text":"https://secwatch.observer/filing/0001274737-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000006/0001274737-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000006/exdx-20240107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:02:08.218148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"080f2498910fe662c98942f66fe94b9b6c392650","claim":"EXAGEN INC. updated its the full year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473724000006/0001274737-24-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}